GRI Bio, Inc. (GRI)
NASDAQ: GRI · Real-Time Price · USD
1.920
-0.010 (-0.52%)
At close: Sep 17, 2025, 4:00 PM EDT
1.950
+0.030 (1.56%)
After-hours: Sep 17, 2025, 7:47 PM EDT
GRI Bio Employees
GRI Bio had 4 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,979,750
Market Cap
4.83M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4 | 0 | - |
| Dec 31, 2023 | 4 | 3 | 300.00% |
| Dec 31, 2022 | 1 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
GRI News
- 6 days ago - GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire
- 4 weeks ago - GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 6 weeks ago - GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment - GlobeNewsWire
- 2 months ago - GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 2 months ago - GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire
- 2 months ago - GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewsWire
- 4 months ago - GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewsWire
- 4 months ago - GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase - GlobeNewsWire